Search
Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read moreImplementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.
Urgent actions are needed now to prevent a collapse of diagnostic testing.
Read moreEvaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER
Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.
Read moreChairs and Members
Chair (2022–2025 term)Philipp Staber, Medical University Vienna (Austria)
Co-chair (2022–2025 term)Caroline Heckman, FIMM, Helsinki (Finland)
SWG Steering Committee members (2022–2025 term)
Jean-Pierre Bourquin, Universitäts-Kinderspital Zürich (Switzerland)
Kirsten Grønbæk, University of Copenhagen (Denmark)
Eva Hellström Lindberg, Karolinska Institutet, Stockholm (Sweden)
Ulrich Jäger, Medical University Vienna (Austria)
Luca Malcovati,…
EHA Ranking 2025
The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version
Position
Company
Priority points
Corporate Level
1
Johnson & Johnson
1. 488,82
Platinum
2
Bristol Myers Squibb
1.
Research training documents for scholars
CBTH documentsCBTH Non-disclosure Agreement
CRTH documentsCRTH Conditions of Acceptance and Participation
CRTH Non-disclosure Agreement
TRTH documentsTRTH Non-disclosure Agreement
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »